2,799
Views
2
CrossRef citations to date
0
Altmetric
Trial Design

Limitations of randomized, controlled, double-blinded studies in determining safety and effectiveness of treatments

& ORCID Icon
Pages 1045-1046 | Received 18 Nov 2021, Accepted 29 Apr 2022, Published online: 13 May 2022

References

  • Ortíz LJ, Vázquez M, Sánchez JL. Bullous pemphigoid and malignancy. Bol Asoc Med P R. 1990;82(10):458–459.
  • March HC. Leukemia in radiologists. Radiology. 1944;43(3):275–278.
  • Ribera J-M, Oriol A. Acute lymphoblastic leukemia in adolescents and young adults. Hematol Oncol Clin. 2009;23(5):1033–1042.
  • Lambert WC, Alhatem A, Lambert MW, et al. What we have learned from the COVID-19 pandemic: time to think outside the box, maybe far outside. Clin Dermatol. 2021;39(1):107–117.
  • Sivabakya TK, Srinivas G. Will the antimalarial drug take over to combat COVID-19? J Public Health. 2020;30:241–244.
  • Bernigaud C, Guillemot D, Ahmed-Belkacem A, et al. Oral ivermectin for a scabies outbreak in a long-term care facility: potential value in preventing COVID-19 and associated mortality. Br J Dermatol. 2021;184(6):1207–1209.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.